| Costs and risks in the management of patients with gastric acid hypersecretion. | |
| | |
MedLine Citation:
|
PMID: 19581810 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
GOALS: To define both risks and costs of optimal care of patients with gastric acid hypersecretion. BACKGROUND: The management of Zollinger-Ellison syndrome and other gastric acid hypersecretory disorders remains challenging. The optimal strategy for follow-up including gastric acid analysis, laboratory studies, and endoscopy is unknown but important given the potential complications from uncontrolled acid secretion. STUDY: Over the last 18 years, patients with gastric acid hypersecretory disorders have been followed prospectively with gastric acid analysis and endoscopy titrating oral lansoprazole and evaluating for complications. Protocol driven charges were calculated using the most recent information available. RESULTS: After 1 year of treatment optimization, 19 of 67 patients had 43 relapses, (once only in 10 patients). Risk markers for relapse included: (1) antrectomy, 67% relapsed versus 21% in unoperated patients; (2) basal acid output >5 mmol/h (risk=5.17); and (3) poor compliance. On treatment, 79% of 58 intact patients (excluding antrectomy) were lesion-free; 11% had only 1 relapse. Thus 90% were well managed with optimized lansoprazole alone. Protocol driven charges exceeded $25,000 the first year and $7000 annually thereafter. CONCLUSIONS: Relapse is infrequent and generally mild with acid secreting status closely monitored. The ideal strategy to balance costs and testing awaits further study. |
| | |
Authors:
|
Basil I Hirschowitz; Naomi Fineberg; C Mel Wilcox; Jean Mohnen; Julie Worthington |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical gastroenterology Volume: 44 ISSN: 1539-2031 ISO Abbreviation: J. Clin. Gastroenterol. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2009-12-22 Completed Date: 2010-03-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7910017 Medline TA: J Clin Gastroenterol Country: United States |
Other Details:
|
Languages: eng Pagination: 28-33 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00204373 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles
/
economics,
therapeutic use* Adult Anti-Ulcer Agents / economics, therapeutic use* Costs and Cost Analysis Endoscopy, Gastrointestinal / methods Female Follow-Up Studies Gastric Acid / secretion* Gastric Acidity Determination Humans Male Middle Aged Prospective Studies Recurrence Young Adult Zollinger-Ellison Syndrome / economics, physiopathology, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prosp...
Next Document: Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Ma...